THERAPY DOSSIER · th-f7051c61e21d

1-(m-chlorophenyl)-piperazine hydrochloride (mCPP)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03962829 ↗NAterminated

The Effect of Oral Administration of Meta-chlorophenylpiperazine (mCPP) on Cognitive Processes, Appetite, and Related Neural Responses in Healthy Lean and Obese Participants

Eating Behavior · Obesity

Enrolment: 32 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23159333 ↗2012Mixed findings

Role of cortical reorganization on the effect of 5-HT pharmacotherapy for spinal cord injury.

RatSpinal cord injuryComplete transectionSprague-DawleyfemaleAcute administration in adulthood, long after neonatal spinal transection

Model: Complete spinal cord transection performed in neonatal rats, studied at adulthood

mCPP increased weight-supported stepping in only a subset of animals, and neurons from responder animals showed greater responsiveness to passive and active forepaw stimulation off-drug than neurons from non-responders, suggesting cortical reorganisation underlies the differential drug response.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…